Navigation Links
Associates of Cape Cod (ACC) and MDS Analytical Technologies Collaborate to Offer a More Robust LAL Endotoxin Assay Platform
Date:7/8/2008

EAST FALMOUTH, Mass. and SUNNYVALE, Calif., July 8 /PRNewswire/ -- Associates of Cape Cod, Inc. (ACC) and MDS Analytical Technologies are pleased to announce the launch of ACC's Chromogenic LAL Endotoxin assay kits utilizing MDS Analytical Technologies' SpectraMax(R) instrument platform and SoftMax(R) Pro GxP software.

ACC and MDS Analytical Technologies collaborated on an FDA 21 CFR part 11 solution for ACC's Chromogenic LAL Endotoxin assay kits. The partnership was based on ACC's validation of MDS Analytical Technologies' VersaMax(TM) monochromator-based absorbance microplate reader using the SoftMax(R) Pro GxP software compliant environment.

ACC offers several chromogenic assays: Pyrochrome(R) and Chromo-LAL for endotoxin detection and Glucatell(R) to detect (1,3)-beta-D-glucan in industrial applications. All methods are optimized for use in microplate detection systems such as the VersaMax(TM) reader.

SoftMax(R) Pro 5 GxP software from MDS Analytical Technologies is the industry standard microplate analysis software, offering extensive data capture and analysis capabilities in a FDA 21 CFR Part 11 compliant environment for MDS Analytical Technologies' SpectraMax(R) line of microplate readers. It includes features that make it particularly well suited to endotoxin and glucan assays.

"We are proud to partner with one of the world's largest manufacturers of assay kits to detect endotoxin in drugs and biological products," said Andy Boorn, President of MDS Analytical Technologies. "Our pharmaceutical and biotechnology customers performing tests on the SpectraMax instrument platform can now increase their capital asset utilization by running LAL assays on SpectraMax readers. In addition, they can leverage the FDA 21 CFR Part 11 compliant system setup with SoftMax Pro GxP software reducing additional compliance costs required with third-party vendor solutions."

ACC President & CEO A.J. Meuse, Ph.D. added, "Partnering with MDS Analytical Technologies, one of the premier bioanalytical instrument companies in the world, further strengthens our ability to meet the variety of instrument and software requirements our customers have for endotoxin and (1,3)-beta-D-glucan analysis. We are pleased to offer our customers the VersaMax(TM) plate reader which provides additional functionality for product release testing in an FDA 21 CFR Part 11 compliant environment."

Customized assay methods for Chromo-LAL, Glucatell(R), Glucatell(R) Diazo, Pyrochrome(R), Pyrochrome(R) Diazo assay kits are available for SoftMax(R) Pro software version 5.2 GxP and greater.

About Associates of Cape Cod, Inc.

Associates of Cape Cod, Inc., based in East Falmouth, MA, is a leader in the field of bacterial endotoxin and beta-glucan detection and a major supplier to the pharmaceutical, medical device and clinical diagnostic industries. A wholly owned subsidiary of Seikagaku BioBusiness Corporation, the Company pioneered the humane use of the horseshoe crab blood extract, Limulus Amebocyte Lysate (LAL), used in the testing of pharmaceuticals, medical devices and biologics, for the presence of potentially toxic endotoxins and glucans. Our products are marketed throughout the world under the trade names Pyrotell(R), Glucatell(R), Pyrochrome(R) and Chromo-LAL. The Company offers contract testing for endotoxins and glucans, and has a research biochemical's division, Northstar BioProducts(TM), specializing in carbohydrate chemistry. The Company also produces a clinical diagnostic test, Fungitell(R), for use by physicians to aid in the diagnosis of invasive fungal infections, and runs the CLIA approved Beacon Diagnostics(R) Laboratory for patient sample analysis. For more information about Associates of Cape Cod, Inc. and our products, please visit our websites at: http://www.acciusa.com or http://www.beacondiagnostics.com or call us at 1-888-395-2221.

About MDS Analytical Technologies

MDS Analytical Technologies is a newly established unit of MDS Inc. and is comprised of two main lines of business. The Sciex product portfolio offers proven market leadership in mass spectrometry. The Molecular Devices product portfolio is the gold standard in high-performance bioanalytical measurement systems that accelerate and improve drug discovery and other life sciences research. Find out more at http://www.moleculardevices.com or http://www.mdssciex.com.

VERSAMAX is a trademark of MDS Analytical Technologies (US) Inc., and SPECTRAMAX and SOFTMAX are registered trademarks of MDS Analytical Technologies (US) Inc.

Contact Info:

For further information contact:

Media:

Cheri Salazar

Director, Global Marketing Communications

Molecular Devices, now part of MDS Analytical Technologies

(408) 548-6316

cheri.salazar@moldev.com


'/>"/>
SOURCE Associates of Cape Cod, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Sign Language Associates and Visual Language Interpreting Combine With GoAmerica to Form Nations Premier Sign Language Interpreting Services Company
2. Jack Henry & Associates Divests Insurance Agency Outsourcing Business Line
3. J.D. Power and Associates Reports: A Vast Majority of Southern California Indian Gaming Casino Customers Express Desire for a Smoke-Free Environment
4. Parks Associates Analysts Present Insights on Broadband, Digital Content, Advertising, Home Systems, and Digital Health at CONNECTIONS(TM)
5. Foundation Radiology Group and Cherry Tree Medical Associates Sign Multi-Year Contract for Diagnostic Services
6. Blue Cross and Blue Shield of Florida Awarded Prestigious J.D. Power and Associates Award for Second Year
7. Booth Radiology Associates Chooses IDC To Complete Its Transition To Digital Imaging
8. Charterhouse Group Partners with MTS Health Investors and Highlander Partners to Acquire Chamberlin Edmonds & Associates, Inc., a Leading Provider of Eligibility Services to Hospitals
9. J.D. Power and Associates Reports: Satisfaction with Health Plans Varies Dramatically From Region To Region, Largely Due to Poor Communication From Insurance Providers
10. Berkery Noyes Represents Princeton Media Associates in Its Sale to HMP Communications/Alta
11. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on BioCurex, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... Dobbs Ferry, New York (PRWEB) , ... April 30, 2016 , ... ... and the Dobbs Ferry campus. The following programs will be expanding due to ... Resources Management (HRM). The expansion will begin this summer. , School ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... , announces the addition Onnit brand Alpha BRAIN and New Mood Daily-Stress Formula ... brain and mood optimization products to the store is just one more way ...
(Date:4/29/2016)... ... April 29, 2016 , ... Dr. Bernie Siegel, ... seller "LOVE, MEDICINE and MIRACLES") addresses touchy topics related to Death live on ... . Dr. Bernie Siegel, author of a plethora of essential books-to-read for ...
(Date:4/29/2016)... ... April 29, 2016 , ... A new study by ... congenital diaphragmatic hernia have better survival rates if surgery is performed early. Approximately ... where the diaphragm fails to form completely, letting abdominal organs into the chest ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... products, announces the Gyrociser, an exercise invention which aids in proper muscle development. ... Scott Cooper, CEO and Creative Director of World Patent Marketing. "Globalization has threatened ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... April 28, 2016 ... George Phillips und Stephen Schmidt ... ArisGlobal®, ein führender Anbieter cloudbasierter ... heute bekannt, dass neue Führungskräfte zum Team ... sind, die vielfältige Erfahrungen mitbringen.  Dies wird ...
(Date:4/28/2016)... -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ... the development of oral drug delivery systems, announced today that ... presented by Joseph Gunnar & Co. LLC, taking ... . Nadav Kidron , CEO of Oramed, will ... Presentation Details:   PIONEERS 2016, presented by ...
(Date:4/27/2016)...  Hologic, Inc. (Nasdaq: HOLX ) ... fiscal second quarter ended March 26, 2016.  GAAP ... 41.2%, and non-GAAP diluted EPS of $0.47 increased ... a reported basis, and 6.3% on a constant ... good quarter, highlighted by 14.6% growth in non-GAAP ...
Breaking Medicine Technology: